GLP-1 clinical studies

Published trials by medicine, population and endpoint, with results and original sources.

Clinical trial results at a glance

Phase 3b · 72 weeks

Wegovy injection

Mean body weight change

Phase 3b · 72 weeks

MounjaroWegovy injection

Mean body weight change

Phase 3b · 64 weeks

Wegovy tablets

Mean body weight change

4 of 19 studies

Search trialsMedicineOutcome

Study	Medicine	Population & follow-up	Published results	Source
SURMOUNT-5Phase 3b · 2025 · 751 participants MounjaroWegovy injectionWithout type 2 diabetes · 72 weeks	MounjaroWegovy injection	Without type 2 diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 10 or 15 mg −20.2% Semaglutide 1.7 or 2.4 mg −13.7%	Paper
SURMOUNT-2Phase 3 · 2023 · 938 participants MounjaroWith type 2 diabetes · 72 weeks	Mounjaro	With type 2 diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 10 mg −12.8% Tirzepatide 15 mg −14.7% Placebo −3.2%	Paper
SURMOUNT-4Phase 3 · 2023 · 670 participants MounjaroAfter tirzepatide lead-in · 52 weeks	Mounjaro	After tirzepatide lead-in52 weeks	Mean body weight change from week 36 to week 88 Continued tirzepatide 10 or 15 mg −5.5% Switched to placebo +14.0%	Paper
SURMOUNT-1Phase 3 · 2022 · 2,539 participants MounjaroWithout diabetes · 72 weeks	Mounjaro	Without diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 5 mg −15.0% Tirzepatide 10 mg −19.5% Tirzepatide 15 mg −20.9% Placebo −3.1%	Paper

Open a study to see doses, comparators and the exact endpoint.